

Rome 30 May 2024 - Takis is pleased to announce that it has been selected among the 13 European companies for the 'IPCEI "**Med4Cure**" project, the first Important Project of Common European Interest in the **Health value chain**.

Med4Cure develops projects to support **research, innovation** and the first industrial deployment of healthcare products, as well as innovative production processes for pharmaceutical products.

The IPCEI Med4Cure project covers research and development projects covering all key stages of the pharmaceutical value chain, from the collection and study of cells, tissues and other samples to sustainable manufacturing technologies of pioneering therapies, including personalized treatments, and application of advanced digital technologies.

"The Takis' project **Zetesis X-eVax** has very ambitious objectives: the first is the creation of a Italian **center of excellence** hosting the entire research chain, from the idea, to preclinical experimentation, GMP production and clinical studies for innovative vaccines and gene therapies; the second is the **development of vaccines against infectious diseases** - a new generation COVID vaccine and one for Malaria - **and cancer**" - explains Luigi Aurisicchio CEO of Takis and scientific director of the Med4Cure project .

"Our project is not only central to the IPCEI network, where we will make our know-how available to European partners, but will provide a strategic asset for *Epidemic Preparedness* and the new technologies for vaccines, antibodies and gene therapy that we are developing" - declares Giuseppe Roscilli, CSO of Takis.

"The quality of research in Italy starts from the excellence of our researchers. Takis, despite being a small biotech, contributes with energy to the offer of new solutions in the field of health, investing in innovation and skills. The **training of young people** in specific, and in particular in research for new generation gene and cell therapies (ATMPs) has always been, and is confirmed today, as our priority" - declares Emanuele Marra, COO of Takis.

"During and after the pandemic, we have learned that the Life Sciences and Biotech sector represent key elements to provide solutions quickly but also for the economies of countries. IPCEI Med4Cure aims to make Europe more competitive through research and production of innovative vaccines and medicines and we are proud to be part of it. The selection of Takis by the European Commission is a great recognition for the contribution we have made and are making to the **medicine of the future** and to the **health of citizens**." - concludes Aurisicchio.

About Takis

Takis is a biotech company created by a group of scientists formerly of Merck Research Laboratories (MRL). The group has more than 15 years of experience and proven expertise in oncology drug discovery and is recognized for the conception and implementation of a number of innovative technologies, including DNA gene therapy. One of Takis' key assets is the expertise with electroporation, a technology that can be used for a variety of clinically useful applications,

from vaccine development to somatic gene therapy. Together with Rottapharm Biotech, Takis developed COVID-eVax, a vaccine against SARS-CoV-2 that was shown to be safe and immunogenic in a Phase 1 clinical trial. Takis' pipeline includes cancer vaccines based on the same technology. Takis is also actively involved in the generation of humanized monoclonal antibodies for use in oncology and infectious diseases, including COVID-19.

For further information on the company, visit the website www.takisbiotech.it

